Organon & Co - Company Profile
Powered by 
All the data and insights you need on Organon & Co in one report.
$295
- Save hours of research time and resources with
our up-to-date Organon & Co Strategy Report
- Understand Organon & Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Organon & Co (Organon) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. Organon is headquartered in Jersey City, New Jersey, the US.
Headquarters
United States of America
Address
30 Hudson Street, Fl 33, Jersey City, New Jersey, 07302
Website
www.organon.com
Telephone
1 551 4306000
No of Employees
10,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OGN (NYSE)
Revenue (2022)
$6.3B
1.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
11.6%
(2022 vs 2021)
Market Cap*
$4.6B
Net Profit Margin (2022)
XYZ
10.0%
(2022 vs 2021)
* As of and is in US$
Organon & Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Women's Health Product | Asmanex |
| Biosimilars | Asmanex Twisthaler |
| Celestone Soluspan | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In November, the company and Samsung Bioepis announced that the U.S. Food and Drug Administration accepted for review the Supplemental Biologics License Application for the interchangeability designation for HADLIMA injection 40 mg/0.4 mL, a biosimilar to Humira (adalimumab). |
| 2023 | Contracts/Agreements | In November, the company entered into a partnership with Sempre Health to motivate eligible patients to refill their prescriptions on time and improve adherence through an innovative pricing program. |
| 2023 | New Products/Services | In July, the company and Samsung Bioepis Co Ltd launched HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), in the US. |
Competitor Comparison
| Key Parameters | Organon & Co | Seagen Inc | Alembic Pharmaceuticals Ltd | Clearside BioMedical Inc | Colorado Center for Reproductive Medicine |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | India | United States of America | United States of America |
| City | Jersey City | Bothell | Vadodara | Alpharetta | Louisville |
| State/Province | New Jersey | Washington | Gujarat | Georgia | Colorado |
| No. of Employees | 10,000 | 3,256 | 14,593 | 30 | 560 |
| Entity Type | Public | Private | Public | Public | Institution |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carrie Cox | Chairman | Executive Board | 2021 | - |
| Kevin Ali | Director; Chief Executive Officer | Executive Board | 2021 | - |
| Matthew Walsh | Chief Financial Officer | Senior Management | - | - |
| Rachel Stahler | Chief Information Officer | Senior Management | - | - |
| Juan Camilo Arjona Ferreira, MD | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward